AKBA vs PTGX vs FOLD vs PRTA vs RARE

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus AKBA's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 466% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Akebia Therapeutics, Inc.

(AKBA) is the more profitable company, earning -2. 3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKBA leads at 9. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Protagonist Therapeutics, Inc.

(PTGX) trades at 30. 6x forward P/E versus 42. 7x for Prothena Corporation plc — 12. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Both have compounded well over 10 years (PTGX: +744. 9%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKBA is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.